On June 29, BeOne Medicines rose 3.01% in regular trading, trading at approximately 171.5 HKD/share, with turnover of 246 million HKD.

On the news front, the stock is rebounding after the market rapidly digested a previously disclosed tax-related overhang. The company announced on June 26 that a wholly-owned domestic subsidiary received notice from local tax authorities to adjust prior tax filings, agreeing to pay additional income tax and late surcharges totaling approximately 446 million RMB. The A-share listed counterpart fell 4.37% on June 27 following the disclosure. The company explicitly stated that no administrative penalty is involved, the matter does not constitute a prior-period accounting error, and it is not expected to have a material adverse impact on financial position or ongoing operations. The supplemental tax amount is roughly equivalent to one month of first-quarter profit.

Additionally, the broader biotech sector rallied strongly, with AKESO up 8.1%, INNOVENT BIO up 5.39%, 3SBIO up 6.66%, and SKB BIO up 5.84%, providing sector-wide tailwinds for the rebound.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)